A bankruptcy judge in Texas rejected a proposal that would have ended most lawsuits saying the products cause ovarian cancer.
Johnson & Johnson shares fell more than 3% on Tuesday after a U.S. bankruptcy judge rejected its $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer.
A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.
A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.
As President Trump's April 2nd “Liberation Day” approaches, the stock market has been selling off due to uncertainties on the impact of the tariff policy implementation intended to even out the presently skewed international playing field.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. A slow March brought mid-single digit percentage dividend boosts from consumer goods company Colgate-Palmolive and defense contractor General Dynamics. Widely-held Johnson & Johnson, Procter & Gamble, and Costco will announce increases in the first half of April.
Two recent catalysts, one technical and one fundamental, have promoted me to adjust my rating on JNJ to a HOLD from my earlier buy rating. Technical trading patterns signal that JNJ is entering a consolidation phase with no clear directional momentum in the near term. In the meantime, JNJ's valuation ratios have expanded, narrowing the discount compared to historical averages and shifting its return/risk profile.
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.